Therapeutic Area

Hypertension

Therapeutic area intelligence for Hypertension with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 3

Companies

AstraZeneca →

Micro Labs →

Sandoz →

Assets

BAXFENDY →

Cardiology →

Hydrochlorothiazide →

Irbesartan →

Recent signals(5)

ClinicalJune 21, 2026

Study on Low-Dose Antihypertensive Therapy in Prehypertensive Chinese Population

The study evaluates low-dose antihypertensive therapy's impact on new-onset hypertension and diabetes in high-normal blood pressure individuals.

StrategyJune 21, 2026

Sandoz receives AP status for Irbesartan and Hydrochlorothiazide ANDA

Sandoz's ANDA077446 for Irbesartan and Hydrochlorothiazide has received an Abbreviated Approval (AP) status.

RegulatoryJune 18, 2026

FDA Accepts Application for BAXFENDY (BAXDROSTAT) from AstraZeneca

The FDA has accepted the New Drug Application for BAXFENDY (BAXDROSTAT) from AstraZeneca.

StrategyJune 9, 2026

FDA Grants Approval for Olmesartan Medoxomil and Hydrochlorothiazide ANDA206371

The FDA has granted approval for ANDA206371, a combination of Olmesartan Medoxomil and Hydrochlorothiazide, submitted by Micro Labs.

RegulatoryJune 1, 2026

AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment

Baxfendy has been approved in the US as the first and only aldosterone synthase inhibitor for adults with hypertension, showing a significant reduction in systolic blood pressure.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.